{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Reyburn R"],"pubmed_abstract":["<h4>Background</h4>There is an ongoing need to assess the impact of pneumococcal conjugate vaccines (PCVs) to guide the use of these potentially valuable but under-utilized vaccines against pneumonia, which is one of the most common causes of post-neonatal mortality.<h4>Methods</h4>We conducted a systematic review of the literature on PCV10 and PCV13 impact on all-cause, radiologically confirmed and severe pneumonia hospitalisation rates as well as all-cause and pneumonia-specific mortality rates. We included studies that were published from 2003 onwards, had a post-licensure observational study design, and reported on any of our defined outcomes in children aged between 0-9 years. We derived incidence rates (IRs), incidence rate ratios (IRRs) or percent differences (%). We assessed all st"],"journal":["Journal of global health"],"pagination":["05002"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9896304"],"repository":["biostudies-literature"],"pubmed_title":["Systematic review on the impact of the pneumococcal conjugate vaccine ten valent (PCV10) or thirteen valent (PCV13) on all-cause, radiologically confirmed and severe pneumonia hospitalisation rates and pneumonia mortality in children 0-9 years old."],"pmcid":["PMC9896304"],"pubmed_authors":["von Mollendorf C","Chua P","Tsatsaronis A","Simon J","Wilkes C","Duke T","Kazi S","Mulholland K","Graham H","Were W","Kevat P","Quach A","Walker P","Russell F","ARI Review group","Neal E","Reyburn R","Nisar YB","Nguyen C","Gwee A","Graham S","Russell FM","Gray A","Hume-Nixon M","Ryan K"],"additional_accession":[]},"is_claimable":false,"name":"Systematic review on the impact of the pneumococcal conjugate vaccine ten valent (PCV10) or thirteen valent (PCV13) on all-cause, radiologically confirmed and severe pneumonia hospitalisation rates and pneumonia mortality in children 0-9 years old.","description":"<h4>Background</h4>There is an ongoing need to assess the impact of pneumococcal conjugate vaccines (PCVs) to guide the use of these potentially valuable but under-utilized vaccines against pneumonia, which is one of the most common causes of post-neonatal mortality.<h4>Methods</h4>We conducted a systematic review of the literature on PCV10 and PCV13 impact on all-cause, radiologically confirmed and severe pneumonia hospitalisation rates as well as all-cause and pneumonia-specific mortality rates. We included studies that were published from 2003 onwards, had a post-licensure observational study design, and reported on any of our defined outcomes in children aged between 0-9 years. We derived incidence rates (IRs), incidence rate ratios (IRRs) or percent differences (%). We assessed all st","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-04T13:08:12.886Z","creation":"2025-04-04T13:08:12.886Z"},"accession":"S-EPMC9896304","cross_references":{"pubmed":["36734192"],"doi":["10.7189/jogh.13.05002"]}}